SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
BOSTON, Feb. 03, 2016 -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced that the Company is scheduled to participate in a fireside chat at the LEERINK Partners
5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 11:30 a.m. ET.
The link to the live audio webcast and replay of the presentation may be accessed on the EPIRUS' website at http://ir.epirusbiopharma.com/events.cfm. The webcast will be archived on the Company's website for a period of three months.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve global patient access to important, cost-effective medicines. EPIRUS' current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®); BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)ii. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets. For more information visit EPIRUS' website at www.epirusbiopharma.com.
Contact Information: For media inquiries: Mike Devine, FleishmanHillard +1-212-453-2324 [email protected] For investor inquiries: Marek Ciszewski, J.D. EPIRUS Biopharmaceuticals +1-617-553-9716 [email protected]
